Correlation Between Protara Therapeutics and Effector Therapeutics
Can any of the company-specific risk be diversified away by investing in both Protara Therapeutics and Effector Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protara Therapeutics and Effector Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protara Therapeutics and Effector Therapeutics, you can compare the effects of market volatilities on Protara Therapeutics and Effector Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protara Therapeutics with a short position of Effector Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protara Therapeutics and Effector Therapeutics.
Diversification Opportunities for Protara Therapeutics and Effector Therapeutics
-0.17 | Correlation Coefficient |
Good diversification
The 3 months correlation between Protara and Effector is -0.17. Overlapping area represents the amount of risk that can be diversified away by holding Protara Therapeutics and Effector Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Effector Therapeutics and Protara Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protara Therapeutics are associated (or correlated) with Effector Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Effector Therapeutics has no effect on the direction of Protara Therapeutics i.e., Protara Therapeutics and Effector Therapeutics go up and down completely randomly.
Pair Corralation between Protara Therapeutics and Effector Therapeutics
Given the investment horizon of 90 days Protara Therapeutics is expected to generate 0.23 times more return on investment than Effector Therapeutics. However, Protara Therapeutics is 4.35 times less risky than Effector Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Effector Therapeutics is currently generating about -0.4 per unit of risk. If you would invest 281.00 in Protara Therapeutics on August 29, 2024 and sell it today you would earn a total of 23.00 from holding Protara Therapeutics or generate 8.19% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 19.05% |
| Values | Daily Returns |
Protara Therapeutics vs. Effector Therapeutics
Performance |
| Timeline |
| Protara Therapeutics |
| Effector Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Protara Therapeutics and Effector Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Protara Therapeutics and Effector Therapeutics
The main advantage of trading using opposite Protara Therapeutics and Effector Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protara Therapeutics position performs unexpectedly, Effector Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will offset losses from the drop in Effector Therapeutics' long position.| Protara Therapeutics vs. Vaccinex | Protara Therapeutics vs. Monopar Therapeutics | Protara Therapeutics vs. Surrozen | Protara Therapeutics vs. Ikena Oncology |
| Effector Therapeutics vs. Indaptus Therapeutics | Effector Therapeutics vs. Jasper Therapeutics | Effector Therapeutics vs. RenovoRx | Effector Therapeutics vs. Ensysce Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Complementary Tools
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |